Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

NCT02880228 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Dexamethasone
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
BIOLOGICAL: Pembrolizumab

Sponsor

Mayo Clinic

Collaborators

[object Object]